BBPWM
NTLA icon

Blue Bell Private Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Blue Bell Private Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.7K Hold
1,757
– – ﹤0.01% 489
2026
Q1 		$22.5K Hold
1,757
– – ﹤0.01% 497
2025
Q4 		$15.8K Hold
1,757
– – ﹤0.01% 510
2025
Q3 		$30.3K Buy
+1,757
New +$21.6K ﹤0.01% 441

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Blue Bell Private Wealth Management's NTLA Position: Q2 2026 in Review

Blue Bell Private Wealth Management held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 1,757 shares worth $29.7K. The position accounts for ﹤0.01% of the portfolio, ranked #489.

Blue Bell Private Wealth Management first reported a position in NTLA in Q3 2025 and has held it in 4 quarters since. The position peaked at $30.3K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Blue Bell Private Wealth Management held 1,757 shares of Intellia Therapeutics worth $29.7K as of Q2 2026.
  • Blue Bell Private Wealth Management left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Blue Bell Private Wealth Management's portfolio in Q2 2026, its #489 holding.
  • Blue Bell Private Wealth Management first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Blue Bell Private Wealth Management's Intellia Therapeutics position peaked at $30.3K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Blue Bell Private Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.